National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2018 (No. 2) (PB 17 of 2018) (Cth)

PB 17 of 2018

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2018 (No. 2)

National Health Act 1953

I, NATASHA PLOENGES, Assistant Secretary (Acting), Private Health Insurance and Pharmacy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 100(2) of the National Health Act 1953.

Dated   26 February 2018

NATASHA PLOENGES

Assistant Secretary (Acting)

Private Health Insurance and Pharmacy Branch

Technology Assessment and Access Division

Department of Health

1. Name of Instrument

(1)This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2018 (No. 2).

(2)This Instrument may also be cited as PB 17 of 2018.

1. Commencement

This Instrument commences on 1 March 2018.

1. Amendment of National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011)

This Instrument amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).

Schedule 1     Amendments

1. Schedule 1, Part 1, entry for Bevacizumab in each of the forms: Solution for I.V. infusion 100 mg in 4 mL; and Solution for I.V. infusion 400 mg in 16 mL

omit from the column headed “Circumstances”:          C6338

1. Schedule 1, Part 2, entry for Bevacizumab [Maximum Amount: 1800; Number of Repeats: 7]

omit from the column headed “Purposes”:    P6338

1. Schedule 4, entry for Bevacizumab

omit:

C6338 P6338 Advanced carcinoma of cervix Grandfathering treatment Patient must have received non-PBS treatment with this drug for this condition prior to 1 September 2016; AND
Patient must not have progressive disease; AND
The treatment must be in combination with platinum-based chemotherapy plus paclitaxel.
Advanced carcinoma of the cervix is defined as persistent carcinoma, recurrent carcinoma or metastatic carcinoma of the cervix.
The patient's Gynaecologic Oncology Group (GOG) performance status and body weight must be documented in the patient's medical records at the time the treatment cycle is initiated. Compliance with Authority Required procedures - Streamlined Authority Code 6338